Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VISEND
PACTR201904781300573Phase 3Recruiting
- Sponsor
- Mylan
- Start
- Apr 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3 trial of dolutegravir, tenofovir disoproxil fumarate, lamivudine, efavirenz, nevirapine and 5 more in human immunodeficiency virus infection (HIV) (4 arms), sponsored by Mylan. Primary endpoints: HIV-1 plasma RNA greater than 1,000 copies/mL at week 144 and Grade 3 or 4 adverse event requiring discontinuation of therapy. Started Apr 2019; status: recruiting.
02
Drugs
dolutegravirtenofovir disoproxil fumaratelamivudineefavirenznevirapine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR201904781300573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201904781300573.